KDM5C and nonpapillary renal cell carcinoma: Inactivating mutations of KDM5C, commonly found in patients with ccRCC, alter glycogen metabolism, leading to increased NADPH and GSH levels and thereby inhibiting ferroptosis; thus, glycogen metabolism in KDM5C-deficient ccRCC is a therapeutic target for the induction of ferroptosis (88).